IASLC 2022 World Conference on Lung Cancer (WCLC 2022)

Industry Symposia are programs held at the IASLC 2022 World Conference on Lung Cancer (IASLC WCLC 2022), are not sponsored or endorsed by the IASLC and are not part of the official IASLC accredited program.

Click on the session titles below to read more about each program.

IS01 - Industry Sponsored Symposium by Abbvie Global: c-Met Dysregulation: Targeted agents and their emerging role in advanced NSCLC

Time: 10:45 – 11:45 CEST | Location: Hall C7

View Program / Invitation (PDF)

Chairs/Speakers

Jair Bar
Alona Zer
Shobhit Baijal

Agenda
Introduction and Opening Remarks (5 min) Jair Bar c-Met testing and challenges associated with biomarker testing in NSCLC patients (15 min) Jair Bar Role of c-MET dysregulation in NSCLC (15 min) Shobhit Baijal Clinical data available on agents targeting c-Met dysregulation in NSCLC (15 min) Alona Zer Q & A (5 min) All Conclusion and Evaluation (5 min) Jair Bar

IS03 - Industry Sponsored Symposium by Mirati Therapeutics: Future Directions in NSCLC: Tailoring Treatment Options

Time: 12:00 – 13:00 CEST | Location: Hall C2

View Program / Invitation (PDF)

Chairs/Speakers

David Planchard
David Carbone
Marina Garassino

Agenda
Welcome and Introduction (5 min) David Planchard The Changing Landscape in NSCLC (10 min) David Planchard New Approaches for Overcoming CPI Resistance in NSCLC (15 min) David Carbone Targeting KRAS: Novel Opportunities for KRASG12C-Driven NSCLC (20 min) Marina Garassino Summary and Q&A (10 min) All

IS04 - Industry Sponsored Symposium by Novartis: Novel Anti–PD-(L)1/anti-TIGIT Combinations: Are these Breaking New Ground in NSCLC?

Time: 12:00 – 13:00 CEST | Location: Hall C1

View Program / Invitation (PDF)

Chairs/Speakers

Barbara Melosky
Giorgio Scagliotti
Riyaz Shah

Agenda
Welcome and Program Overview (5 min) Barbara Melosky Laying the Foundation: The need to go further with IO in advanced NSCLC (15 min) Riyaz Shah Building Upward: Emerging anti-PD-(L)1/anti-TIGIT combinations in NSCLC (15 min) Giorgio Scagliotti Panel Discussion: How to break new ground with anti-TIGIT combinations (15 min) All Q&A Session (10 min) All

IS05 - Industry Sponsored Symposium by Merck Kgaa Darmstadt: Decisive Moments in the Treatment of MET exon 14 skipping NSCLC

Time: 13:15 - 14:15 CEST | Location: Hall C7

View Program / Invitation (PDF)

Chairs/Speakers

Sanjay Popat
Sonja Loges
Paul Paik
Enriqueta Felip

Agenda
A moment to welcome you (5 min) Sanjay Popat Take a moment to consider identification and treatment (5 min) All A moment of clarity: Has our VISION1 for METex14 skipping become a reality? (15 min) All Seize the moment: The benefits of early treatment (15 min) All Make every moment matter: Optimising treatment (15 min) All A moment to reflect on METex14 skipping (5 min) Sanjay Popat

IS06 - Industry Sponsored Symposium by Takeda: Precision Medicine in Lung Cancer: Learnings from Established and Emerging Targets

Time: 13:15 - 14:15 CEST | Location: Hall C8

View Program / Invitation (PDF)

Chairs/Speakers

Jyoti D. Patel
Stephen Liu
Daniel Tan

Agenda

Welcome and Introduction (5 min)
Jyoti D. Patel
Successes, Challenges, and Lessons Learned in the Evolution of Precision Medicine (10 min)
Jyoti D. Patel
Treatment Selection in ALK-Positive Metastatic NSCLC: Navigating Treatment for an Established Biomarker (20 min)
Stephen Liu
Current and Emerging Treatment Standards in EGFR Exon 20 Insertion+ Metastatic NSCLC (15 min)
Daniel Tan
Panel discussion and Q&A (10 min)
All

IS07 - Satellite CME Symposium by Liberum IME, Supported by Bayer, Eli Lilly and Illumina: Optimizing Biomarker-Driven Therapy in NSCLC

Time: 14:30 - 15:30 CEST | Location: Hall C1

View Program / Invitation (PDF)

Chairs/Speakers

Fernando López-Ríos
Robin Cornelissen

Agenda

Welcome, pre-activity information & pre-assessment (5 min)
Fernando López-Ríos
Implementation and interpretation of biomarker testing in NSCLC (10 min)
Fernando López-Ríos
Biomarker-driven approaches: Combined prevalence and individual outcomes (10 min)
Robin Cornelissen
How to use Classroom to ClinicTM (5 min)
Fernando López-Ríos
Workshop: Applying guideline best practice to case studies (15 min)
All
Post-assessment and commitment to change (3 min)
All
Q&A session (7 min)
All
Close (5 min)
Fernando López-Ríos

IS08 - Industry Sponsored Symposium by Pfizer: Is it Time to Raise the Bar for ALK+ NSCLC Patients?

Time: 14:30 - 15:30 CEST | Location: Hall C2

View Program / Invitation (PDF)

Chairs/Speakers

Justin Gainor
Alessandra Bearz
Rosario García Campelo

Agenda

Welcome and introduction (5 min)
Justin Gainor
New data and updated expectations for first‑line therapy (10 min)
Alessandra Bearz
Managing AEs and keeping patients on treatment (10 min)
Rosario García Campelo
What next? Options after progression on 2nd- and 3rd-generation TKIs (10 min)
Alessandra Bearz
The future of ALK+ NSCLC (10 min)
Justin Gainor
Q&A Session (10 min)
All
Summary and close (5 min)
Justin Gainor

IS09 - Industry Sponsored Symposium by Astrazeneca: Embarking on the next chapter in SCLC: Challenges and Opportunities

Time: 15:45 – 16:45 CEST | Location: Hall C7

View Program / Invitation (PDF)

Chairs/Speakers

Lauren Byers
Andrea Ardizzoni
Taofeek Owonikoko
Keunchil Park

Agenda
Introduction Lauren Byers Current treatment landscape for ES-SCLC and the unmet need Andrea Ardizzoni Panel discussion: Improving outcomes for patients with SCLC – today and tomorrow All Audience Q&A All Closing remarks Lauren Byers

IS10 - Industry Sponsored Symposium by Sanofi: A New Frontier: Emerging Biomarkers and Antibody-Drug Conjugates in Advanced NSCLC

Time: 15:45 – 16:45 CEST | Location: Hall C8

View Program / Invitation (PDF)

Chairs/Speakers

David Gandara
Ming Tsao
Alastair Greystoke

Agenda
Welcome and Overview of the Current Treatment Algorithms for Patients with NSCLC (15 min) David Gandara What, How, and Where Do We Test Emerging Biomarkers? (15 min) Ming Tsao Emerging and Novel Therapies in Patients without Driver Mutations (15 min) Alastair Greystoke Roundtable Discussion (10 min) All Final Remarks (5 min) David Ganda

IS11 - Industry Sponsored Symposium by Amgen Inc: Driving Advancements in the Treatment of Lung Cancer

Time: 13:15 – 14:15 CEST | Location: Hall C8

View Program / Invitation (PDF)

Chairs/Speakers

Luis Paz-Ares
Natasha Leighl
Michael Boyer

Agenda
Welcome and introduction to innovative treatments for new targets in lung cancer (15 min) Luis Paz-Ares A step forward: KRASG12C inhibitors in NSCLC today and in the future (15 min) Natasha Leighl Striving for improvement in SCLC: Off-the-shelf T cell engaging therapies targeting DLL3 (15 min) Michael Boyer Panel discussion and Q&A (15 min) All

IS12 - Industry Sponsored Symposium by Astrazeneca: Expanding Horizons in Metastatic NSCLC: Unmet Need and Future Directions

Time: 13:15 – 14:15 CEST | Location: Hall C7

View Program / Invitation (PDF)

Chairs/Speakers

John Heymach
Niels Reinmuth
Elena Guerini-Rocco

Agenda
Welcome and introduction (5 min) John Heymach Biomarker identification of hard-to-treat patients: shining a spotlight on unmet need (15 min) Niels Reinmuth Seeing the unseen: techniques and practical strategies for broad molecular profiling (15 min) Elena Guerini-Rocco Panel discussion and Q&A (15 min) All

IS13 - Industry Sponsored Symposium by Janssen Pharmaceuticals: Expanding Horizons for the Targeted Management of EGFR-Mutant NSCLC

Time: 13:15 – 14:15 CEST | Location: Strauss 3

View Program / Invitation (PDF)

Chairs/Speakers

Martin Reck
Umberto Malapelle
Maximilian Hochmair
Sabine Merkelbach-Bruse
Jordi Remon

Agenda
Welcome and introductions (2 min) What’s new in molecular diagnostics for EGFR-mutant NSCLC? (15 min) EGFR exon 20 insertion mutations: A new target for an old mutation (15 min) Novel approaches in treatment-resistant advanced EGFR-mutant NSCLC (15 min) Live Q&A (10 min) Key learnings and closing remarks (3 min)

IS14 - Industry Sponsored Symposium by RMEI, Supported by Regeneron and Sanofi: Harnessing the Full Potential of Immunotherapy in Frontline Treatment of Locally Advanced or Metastatic NSCLC

Time: 18:00 - 19:00 CEST | Location: Hall C7

View Program / Invitation (PDF)

Chairs/Speakers

Jared Weiss
Aleš Ryška
Mihaela Aldea

Agenda
Opening Ceremonies (5 min) Jared Weiss Use of Biomarker Testing in Advanced NSCLC (15 min) Aleš Ryška Selecting Frontline Immunotherapy in Advanced NSCLC (15 min) Jared Weiss Managing Immunotherapy-Related Adverse Events in NSCLC (15 min) Mihaela Aldea Closing Ceremonies (10 min) Jared Weiss

IS20 - Industry Sponsored Symposium by Astrazeneca: Current and Future Management of Patients with Advanced EGFRm NSCLC Progressing on Third-generation EGFR-TKIs

Time: 13:30 – 14:30 CEST | Location: Hall C7

View Program / Invitation (PDF)

Chairs/Speakers

Pasi Jänne
Myung-Ju Ahn
Michelle Shiller

Agenda

Welcome & Introduction (3 min)
Pasi Jänne
Current management of patients progressing on third-generation EGFR-TKIs (10 min)
Myung-Ju Ahn
Evolving treatment landscape for patients with EGFRm advanced NSCLC and c-MET-driven resistance to third-generation EGFR-TKIs (15 min)
Pasi Jänne
Optimal biomarker testing to identify patients with MET-driven resistance (15 min)
Michelle Shiller
Panel discussion and Q&A (15 min)
All
Summary and close (2 min)
Pasi Jänne

IS21 - Industry Sponsored Symposium by Daiichi Sankyo, Inc.: The Expanding Toolbox: Key Updates for ADCs in Lung Cancer

Time: 13:30 – 14:30 CEST | Location: Strauss 3

View Program / Invitation (PDF)

Chairs/Speakers

Michael Thomas
Tony Mok
Charles Rudin

Agenda
Welcome and Introduction (2 min) Michael Thomas Emerging Targets for Therapeutic Strategies (20 min) Michael Thomas Key Data Releases for ADCs in NSCLC (20 min) Tony Mok Implications of Emerging Data for SCLC (10 min) Charles Rudin Q&A (8 min) All

IS22 - Industry Sponsored Symposium by Sanofi Regeneron Alliance: Breaking Barriers with Immunotherapy in Squamous Cell Carcinoma of the Lung: Challenges and Opportunities in Management

Time: 13:30 – 14:30 CEST | Location: Hall C8

View Program / Invitation (PDF)

Chairs/Speakers

Federico Cappuzzo
Jürgen Wolf
Johan Vansteenkiste

Agenda
Welcome and Introduction (5 min) Federico Cappuzzo Focusing on the Challenge of Squamous Lung Cancer (15 min) Jürgen Wolf Immunotherapy Outcomes for Advanced Squamous Cancers of the Lung (15 min) Johan Vansteenkiste Case Study Panel Discussion, Ask the Faculty and Concluding Remarks (25 min) All

IS23 - Satellite CME Symposium by Medscape Oncology Global, Supported by Daiichi Sankyo, Inc.: The Potential of Antibody-Drug Conjugates in Non-Small Cell Lung Cancer From Mechanism to Action

Time: 18:00 - 19:00 CEST | Location: Strauss 3

View Program / Invitation (PDF)

Chairs/Speakers

Hossein Borghaei
Ticiana Leal
Antonio Passaro

Agenda
Welcome and Introduction (3 min) Hossein Borghaei Mechanism of Action and Targets of ADCs in NSCLC (15 min) Antonio Passaro ADCs in NSCLC: What Do the Data Show? (17 min) Hossein Borghaei ADCs in the Clinic: Challenges and Perspectives (15 min) Ticiana Leal Audience Q&A (9 min) All Concluding Remarks (1 min) Hossein Borghaei

IS24 - Industry Sponsored Symposium by MSD: New Frontiers in the Management of NSCLC

Time: 18:00 - 19:00 CEST | Location: Hall C7

View Program / Invitation (PDF)

Chairs/Speakers

Solange Peters
Benjamin Besse
David Finley

Agenda
Welcome and introductions (5 min) Solange Peters Evolving treatment landscape in metastatic NSCLC (10 min) Solange Peters Emergence of immuno-oncology in early-stage operable NSCLC (15 min) Benjamin Besse A surgeon’s perspective on treatment in early-stage operable NSCLC (15 min) David J. Finley Panel discussion and Q&A (15 min) All Closing Remarks Solange Peters

INDUSTRY SPONSORED SYMPOSIA AND SATELLITE CME SYMPOSIA

Contact

Stay Connected